CLUSTER,LABEL,X,Y,RANK
0,Age Requirements,12.781787006155753,-66.0295181121781,3
1,Gender and Reproductive Status,14.65783452584463,-52.51789235507741,31
2,Metastatic Disease Confirmation,17.732846131321597,20.961232919500187,2
3,Breast Cancer Diagnosis Requirements,50.76914313979361,-1.1717305185702154,9
4,Stable brain metastases allowed,-20.402349891201144,12.720161574381974,32
5,Treatment Tolerance and Recovery,-12.811754670222944,29.43114009602064,10
6,ECOG Performance Status Criteria,-15.49179933847903,70.42640901638279,5
7,Organ Function Requirements,-61.92910248908838,3.6858367324185313,4
9,Normal liver function criteria required,75.96246510662445,-9.08608227076044,28
10,Normal Laboratory Values,-23.918161744064427,5.021143211359563,14
11,Contraception and Pregnancy Requirements,55.914352429230405,42.75643338782404,11
12,Adequate coagulation function required,-52.16591796875,-5.944617563754667,6
13,Life Expectancy Requirements,52.697471007663225,-56.07014672537036,33
14,Tumor Tissue and Biopsy Requirements,-29.902361330890017,-7.200298617262669,13
15,Ability to swallow oral medications,-62.47223907580479,-23.32077022250608,12
16,Informed Consent Requirements,-50.418580670812965,-45.83115516140139,39
17,Histologically confirmed invasive breast cancer,6.5202755945539135,-27.154958273592367,7
18,Measurable Disease Criteria,-36.1119357499087,28.22309958015879,30
19,Prior Treatment Conditions,20.984668862043364,5.786396176402537,8
20,Minimum LVEF of 50% required,-81.87673015594483,-16.647156143188475,1
21,Diagnosed breast cancer patients only,11.144446635212022,-16.323317645610064,36
23,Willingness and ability to comply,-36.79711516158699,-29.890856899729595,22
25,Absolute neutrophil count ≥ 1.5 x 10^9/L,-55.67573691943644,53.38193480822505,27
26,Minimum platelet count requirement,71.20134768925661,14.508238535400825,18
28,Hemoglobin and albumin thresholds,51.81887028849544,-33.46422920592677,15
32,"Early-stage, non-metastatic breast cancer",-1.6358298763117325,-15.143705598963132,24
36,Chemotherapy eligibility for breast cancer,10.33343413698318,-2.239227505118099,29
37,Good performance status required,-27.94934036750202,68.9710816375969,34
38,Adequate cardiac function (LVEF ≥ 50%),-77.50097406827487,-22.05659827819237,26
40,Recovery and washout from treatments,-8.104487410386403,1.6960703882409467,23
41,Hormone receptor status assessment required,54.354903737104486,-21.107685929513984,17
43,Postmenopausal women with defined criteria,34.99642676892488,-48.67372930360877,35
44,Documented disease progression after treatment,-3.770091021203832,18.09925422643962,25
45,No evidence of disease recurrence,-5.3711599350528685,-5.964941406354113,19
47,Dose escalation and expansion eligibility,-0.6547221936279638,-34.112395787389026,21
48,Genetic mutation or biomarker presence,26.141550808022284,18.88603084773616,37
49,Diverse cancer types and treatment histories,20.985349303886984,6.93990834115663,20
50,BMI between 18 and 32 kg/m²,-74.1948287997927,42.98375647408621,40
51,All criteria must be met,-13.077964078428018,-39.85461741487185,38
53,Hormonal therapy eligibility and management,22.435540635864456,-27.833346400013216,41
55,Controlled viral infections required,-48.0388822879921,9.30643519901094,16
